Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Cravit Ranked No. 1 on Both HP and GP Markets: Rep Track Survey
August 31, 2009
- Full-Scale Flu Epidemic May Have Begun: Health Minister
August 31, 2009
- Makers' FY2009 1st Qtr Business Roundup -2-
August 31, 2009
- GSK Starts Adjusting Shipments of Relenza due to Rush of Orders
August 31, 2009
- Makers' FY2009 1st Qtr Business Roundup -1-
August 31, 2009
- Sales of Ethical Drugs Up 7.9% in June: Crecon
August 31, 2009
- Kowa Licenses Livalo to MTPC in Taiwan, Indonesia
August 31, 2009
- SELF-MEDICATION NEWS IN BRIEF
August 31, 2009
- DSP to Transform Itself into Global Research-Driven Pharma: President Tada
August 31, 2009
- Wholesalers Should Increase Profits by Offering Value through MSs: Mr Bessho
August 24, 2009
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
August 24, 2009
- Wholesalers' Gross Profit Rate Down to 7.09%
August 24, 2009
- Drug Costs Down 1.6% in Municipal Hospitals in FY2008
August 24, 2009
- Top-Four Wholesalers' FY2009 1st Qtr Business Roundup
August 24, 2009
- GE Healthcare, Terumo Agree on Joint Marketing
August 24, 2009
- Makers' FY2009 1st Qtr Business Roundup
August 24, 2009
- GE Healthcare Integrates Two Subsidiaries to Create GE Healthcare Japan
August 24, 2009
- AZ, Astellas to Copromote Symbicort in Japan
August 24, 2009
- SELF-MEDICATION NEWS IN BRIEF
August 24, 2009
- Daiichi Sankyo, Eli Lilly Launch Effient in the US
August 24, 2009
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…